Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY26 results · Jan–Mar 2026
Pfizer reported revenue from operations of ₹629.23 crore (up 6.3% from Q4 FY25) and net profit of ₹199.82 crore (down 39.6% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a standalone basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 629.23 | 591.91 | +6.3% | 645.03 | −2.4% |
| Other income | 40.72 | 44.58 | −8.7% | 38.21 | +6.6% |
| Total income | 669.95 | 636.49 | +5.3% | 683.24 | −1.9% |
| Profit before tax | 268.82 | 425.80 | −36.9% | 191.95 | +40.0% |
| Net profit for the period | 199.82 | 330.94 | −39.6% | 141.84 | +40.9% |
| EPS, basic (₹) | 43.68 | 72.34 | −39.6% | 31.01 | +40.9% |
| Net margin (%) | 31.8 | 55.9 | 22.0 |
Standalone
- Filed with BSE
- 12 May 2026, 21:09 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE